# Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

> **NCT05798793** · PHASE3 · RECRUITING · sponsor: **Hospital of Stomatology, Wuhan University** · enrollment: 309 (estimated)

## Conditions studied

- Oral Squamous Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab plus TP
- **DRUG:** TP

## Key facts

- **NCT ID:** NCT05798793
- **Lead sponsor:** Hospital of Stomatology, Wuhan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-21
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 309 (ESTIMATED)
- **Last updated:** 2024-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05798793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05798793, "Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05798793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*